#United States #San Antonio #Eli Lilly #Verzenio #Inluriyo

Eli Lilly Focuses on Advancements in Breast Cancer Treatments at SABCS 2025

Eli Lilly and Company (NYSE: LLY) will make a significant impact at the upcoming San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9–12, 2025. The company will showcase important data reflecting its progress in tackling hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer, which represents the most prevalent type of breast cancer.

Latest Updates from Clinical Trials

1. Inluriyo™ (imlunestrant)

In a highly anticipated late-breaking oral presentation, Lilly will unveil updated findings from the Phase 3 EMBER-3 trial. This study examines the efficacy of Inluriyo, both as a standalone treatment and in combination with Verzenio® (abemaciclib), specifically in patients battling ER+, HER2– metastatic breast cancer. Key points to be discussed include overall survival (OS), progression-free survival (PFS), and time to chemotherapy (TTC). Additionally, a poster presentation will highlight exploratory analyses that delve into early changes in circulating tumor DNA (ctDNA) and their correlation with clinical outcomes.

2. Verzenio® (abemaciclib)

In another pivotal presentation, Lilly will share findings from a subgroup analysis of the Phase 3 monarchE trial. This research investigates the combination of adjuvant abemaciclib with endocrine therapy based on nodal status in patients facing HR+, HER2– high-risk early breast cancer. Results from this study will build on previous data presented at ESMO 2025 that indicated improved overall survival and sustained enhancements in invasive disease-free survival (IDFS) as well as distant relapse-free survival (DRFS).

3. LY4064809 / STX-478

Finally, findings from the ongoing Phase 1/2 trial (PIKALO-1) involving LY4064809, a pan-mutant-selective PI3Kα inhibitor, will also be highlighted. This research focuses on patients with PIK3CA-mutant HR+, HER2– advanced breast cancer. The poster presentation will provide updated data encompassing safety, efficacy, and biomarker analyses, as well as insights across patient subgroups defined by pre-diabetic, diabetic, and non-diabetic statuses. Relevant to stakeholders, LY4064809 is on track to transition into the Phase 3 PIKALO-2 study.

Commitment to Breast Cancer Research

Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, remarked, "At SABCS 2025, we're proud to showcase new data across our portfolio of investigational and approved breast cancer medicines, addressing the three most important biologic targets in HR+ breast cancer: CDK4/6, the estrogen receptor, and PI3K. These presentations reflect the ongoing momentum of Lilly’s breast oncology portfolio and our dedication to delivering meaningful advancements for those living with breast cancer."

Presentation Schedule

The following is a glimpse of what attendees can expect:

• - Inluriyo: Oral Presentation on updated efficacy results from the Phase 3 EMBER-3 trial by Komal Jhaveri on December 12 at 10:45-11:00 a.m. CST.
• - Real-World ESR1 Mutation Testing: Poster session presenting testing and positivity rates in patients with ER+/HER2- metastatic breast cancer by Lindsay Williams on December 10 from 12:30-2:00 p.m. CST.
• - Patient Experience Analysis: Erica Fortune will lead a poster presentation discussing patient experiences related to intramuscular versus oral endocrine therapy in metastatic breast cancer on December 10.

About Lilly

Eli Lilly has been at the forefront of medical innovation for nearly 150 years. The company is dedicated to turning scientific discoveries into healing solutions for people worldwide, working relentlessly to address the most significant health challenges. From redefining diabetes care and advancing Alzheimer’s treatment to transforming difficult cancers into manageable conditions, Lilly's mission is centered on making life better for millions. Through commitment to diversity in clinical trials and ensuring accessible medicines, Lilly continues to be a beacon of hope in healthcare.

Conclusion

As the SABCS progresses, it is clear that Eli Lilly's contributions to the field of breast oncology will resonate throughout the research community and beyond, paving the path towards improved outcomes for breast cancer patients everywhere.